Human East African Trypanosomiasis: Symptoms, Diagnosis & Treatment
“`html
MPox Vaccine Effectiveness Wanes Over Time, But Remains Protective
Table of Contents
The JYNNEOS vaccine, the primary tool used to combat the 2022-2023 MPox outbreak, provides important initial protection against the virus. however, new research indicates that its effectiveness diminishes over time, though it continues to offer substantial protection against severe illness, hospitalization, and death. This analysis, published on October 23, 2025, provides critical insights into the long-term durability of vaccine-induced immunity.
The Study: Tracking Vaccine Effectiveness
Researchers analyzed data from a large cohort of individuals across the United States who received the JYNNEOS vaccine during the MPox outbreak. The study meticulously tracked infection rates among vaccinated and unvaccinated individuals over a period of 18 months. The analysis focused on identifying the rate at which protection decreased following the two-dose primary series.
The study population included individuals with and without known HIV status,allowing researchers to assess whether immunocompromised individuals experienced different rates of waning immunity. Data was collected through a combination of public health surveillance systems and electronic health records.
Key Findings: How Protection Declines
The study revealed a clear pattern of declining vaccine effectiveness. Initially, the JYNNEOS vaccine demonstrated approximately 89% effectiveness in preventing MPox infection. Though, this protection decreased to 70% after 6-12 months, and further declined to 55% after 12-18 months. Importantly, even with reduced effectiveness, the vaccine continued to provide strong protection against severe outcomes.
Specifically, the vaccine maintained approximately 90% effectiveness in preventing hospitalization and 85% effectiveness in preventing death related to MPox, even after 18 months. This suggests that while breakthrough infections may become more common, the vaccine considerably reduces the risk of serious illness.
| Time Since Vaccination | Vaccine Effectiveness (Preventing Infection) | Vaccine Effectiveness (Preventing Hospitalization) | Vaccine Effectiveness (Preventing Death) |
|---|---|---|---|
| Initial (0-6 months) | 89% | 95% | 98% |
| 6-12 months | 70% | 92% | 96% |
| 12-18 months | 55% | 90% | 85% |
Who is Most Affected?
The study indicated that individuals with weakened immune systems, particularly those living with HIV, experienced a more rapid decline in vaccine effectiveness. This highlights the importance of prioritizing booster doses for these vulnerable populations. Researchers observed that individuals with higher viral loads at the time of infection were more likely to experiance severe illness, even if they had been vaccinated.
The data also suggested that the emergence of new MPox viral variants may contribute to waning immunity. Ongoing genomic surveillance is crucial for monitoring viral evolution and assessing the potential impact on vaccine effectiveness.